Grant Title: NATIONAL COOPERATIVE DRUG DISCOVERY AND DEVELOPMENT GROUPS (NCDDDG) FOR THE TREATMENT OF MENTAL DISORDERS, DRUG OR ALCOHOL ADDICTION (UM1,U19)

Funding Opportunity Number: PAR-13-087, PAR-13-086. CFDA Number(s): 93.242, 93.273, 93.279.

Agency/Department: Department of Health and Human Services, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Area of Research: Create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat and to study mental illness, drug or alcohol addiction.


Amount: Application budgets are not limited, but need to reflect actual needs of the proposed project. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIH program staff at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Length of Support: Up to five years.

Eligible Applicants: Public and State controlled institutions of higher education. See full announcement for other eligible applicants.

Summary: The purpose of the National Cooperative Drug Discovery/Development Group (NCDDG) Program is to create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat and to study mental illness, drug or alcohol addiction. The objectives of this program are to: accelerate innovative drug discovery; develop pharmacologic tools for basic and clinical research on mental disorders, or drug or alcohol addiction; develop and validate models for evaluating novel therapeutics for mental disorders; and support early phase human clinical testing to rapidly assess the safety and efficacy of promising drug candidates and new indications for IND-ready agents for the treatment of mental disorders or alcohol addiction. The National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) encourage applications to advance the discovery, preclinical development, and proof of concept testing of new, rationally based candidate agents to treat mental disorders or drug or alcohol addiction, and to develop novel ligands as tools to further characterize existing or to validate new drug targets. Partnerships between academia and industry are strongly encouraged.